A predictive model for early recurrence of colorectal-cancer liver metastases based on clinical parameters

被引:16
作者
Dai, Siqi [1 ,2 ]
Ye, Yao [1 ,2 ]
Kong, Xiangxing [1 ,2 ]
Li, Jun [1 ,2 ]
Ding, Kefeng [1 ,2 ]
机构
[1] Zhejiang Univ, Affiliated Hosp 2, Dept Colorectal Surg, Sch Med, 88 Jiefang Rd, Hangzhou 310009, Zhejiang, Peoples R China
[2] Zhejiang Univ, Affiliated Hosp 2, Key Lab Mol Biol Med Sci,Sch Med, Canc Inst,Key Lab Canc Prevent & Intervent,China, Hangzhou, Zhejiang, Peoples R China
基金
中国国家自然科学基金; 中国博士后科学基金;
关键词
colorectal cancer; liver metastases; early recurrence; prediction model; post-operative surveillance; CURATIVE RESECTION; HEPATIC RESECTION; RADIOFREQUENCY ABLATION; LYMPHOCYTE RATIO; POOR-PROGNOSIS; TERM SURVIVAL; RISK-FACTORS; MULTICENTER; SURGERY; CHEMOTHERAPY;
D O I
10.1093/gastro/goaa092
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Background: The prognosis for patients with colorectal-cancer liver metastases (CRLM) after curative surgery remains poor and shows great heterogeneity. Early recurrence, defined as tumor recurrence within 6months of curative surgery, is associated with poor survival, requiring earlier detection and intervention. This study aimed to develop and validate a bedside model based on clinical parameters to predict early recurrence in CRLM patients and provide insight into post-operative surveillance strategies. Material and methods: A total of 202 consecutive CRLM patients undergoing curative surgeries between 2012 and 2019 were retrospectively enrolled and randomly assigned to the training (n=150) and validation (n=52) sets. Baseline information and radiological, pathological, and laboratory findings were extracted from medical records. Predictive factors for early recurrence were identified via a multivariate logistic-regression model to develop a predictive nomogram, which was validated for discrimination, calibration, and clinical application. Results: Liver-metastases number, lymph-node suspicion, neurovascular invasion, colon/rectum location, albumin and post-operative carcinoembryonic antigen, and carbohydrate antigen 19-9 levels (CA19-9) were independent predictive factors and were used to construct the nomogram for early recurrence after curative surgery. The area under the curve was 0.866 and 0.792 for internal and external validation, respectively. The model significantly outperformed the clinical risk score and Beppu's model in our data set. In the lift curve, the nomogram boosted the detection rate in post-operative surveillance by two-fold in the top 30% high-risk patients. Conclusion: Our model for early recurrence in CRLM patients after curative surgeries showed superior performance and could aid in the decision-making for selective follow-up strategies.
引用
收藏
页码:241 / 251
页数:11
相关论文
共 51 条
[41]   Role of thermal ablation in the management of colorectal liver metastasis [J].
Takahashi, Hideo ;
Berber, Eren .
HEPATOBILIARY SURGERY AND NUTRITION, 2020, 9 (01) :49-58
[42]   Short time to recurrence after hepatic resection correlates with poor prognosis in colorectal hepatic metastasis [J].
Takahashi, Shinichiro ;
Konishi, Masaru ;
Nakagohri, Toshio ;
Gotohda, Naoto ;
Saito, Norio ;
Kinoshita, Taira .
JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2006, 36 (06) :368-375
[43]   Risk factors for recurrence in stage II/III colorectal cancer patients treated with curative surgery: The impact of postoperative tumor markers and an infiltrative growth pattern [J].
Tokodai, Kazuaki ;
Narimatsu, Hiroto ;
Nishida, Akiko ;
Takaya, Kai ;
Hara, Yasuyuki ;
Kawagishi, Naoki ;
Hashizume, Eiji ;
Ohuchi, Noriaki .
JOURNAL OF SURGICAL ONCOLOGY, 2016, 114 (03) :368-374
[44]   The role of interventional oncology in the treatment of colorectal cancer liver metastases [J].
Tsitskari, Maria ;
Filippiadis, Dimitris ;
Kostantos, Chrysostomos ;
Palialexis, Kostantinos ;
Zavridis, Periklis ;
Kelekis, Nikolaos ;
Brountzos, Elias .
ANNALS OF GASTROENTEROLOGY, 2019, 32 (02) :147-155
[45]   Advanced colorectal cancer: ESMO Clinical Practice Guidelines for treatment [J].
Van Cutsem, E. ;
Nordlinger, B. ;
Cervantes, A. .
ANNALS OF ONCOLOGY, 2010, 21 :v93-v97
[46]   Safety and efficacy of first-line bevacizumab with FOLFOX, XELOX, FOLFIRI and fluoropyrimidines in metastatic colorectal cancer: the BEAT study [J].
Van Cutsem, E. ;
Rivera, F. ;
Berry, S. ;
Kretzschmar, A. ;
Michael, M. ;
DiBartolomeo, M. ;
Mazier, M. -A. ;
Canon, J. -L. ;
Georgoulias, V. ;
Peeters, M. ;
Bridgewater, J. ;
Cunningham, D. .
ANNALS OF ONCOLOGY, 2009, 20 (11) :1842-1847
[47]   A multicentre study of capecitabine, oxaliplatin plus bevacizumab as perioperative treatment of patients with poor-risk colorectal liver-only metastases not selected for upfront resection [J].
Wong, R. ;
Cunningham, D. ;
Barbachano, Y. ;
Saffery, C. ;
Valle, J. ;
Hickish, T. ;
Mudan, S. ;
Brown, G. ;
Khan, A. ;
Wotherspoon, A. ;
Strimpakos, A. S. ;
Thomas, J. ;
Compton, S. ;
Chua, Y. J. ;
Chau, I. .
ANNALS OF ONCOLOGY, 2011, 22 (09) :2042-2048
[48]  
Yamauchi K, 2016, ANTICANCER RES, V36, P2175
[49]   Prognosis Value of Platelet Counts, Albumin and Neutrophil-Lymphocyte Ratio of Locoregional Recurrence in Patients with Operable Head and Neck Squamous Cell Carcinoma [J].
Ye, Jing ;
Liao, Bing ;
Jiang, Xiaohua ;
Dong, Zhihuai ;
Hu, Sunhong ;
Liu, Yuehui ;
Xiao, Mang .
CANCER MANAGEMENT AND RESEARCH, 2020, 12 :731-741
[50]   Pan-Asian adapted ESMO consensus guidelines for the management of patients with metastatic colorectal cancer: a JS']JSMO-ESMO initiative endorsed by CSCO, KACO, MOS, SSO and TOS [J].
Yoshino, T. ;
Arnold, D. ;
Taniguchi, H. ;
Pentheroudakis, G. ;
Yamazaki, K. ;
Xu, R. -H. ;
Kim, T. W. ;
Ismail, F. ;
Tan, I. B. ;
Yeh, K. -H. ;
Grothey, A. ;
Zhang, S. ;
Ahn, J. B. ;
Mastura, M. Y. ;
Chong, D. ;
Chen, L. -T. ;
Kopetz, S. ;
Eguchi-Nakajima, T. ;
Ebi, H. ;
Ohtsu, A. ;
Cervantes, A. ;
Muro, K. ;
Tabernero, J. ;
Minami, H. ;
Ciardiello, F. ;
Douillard, J. -Y. .
ANNALS OF ONCOLOGY, 2018, 29 (01) :44-70